arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

Vistagen Therapeutics, Inc.

VTGN
$0.36 ▲ +0.11 (+41.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
13
Health
Poor
Bearish
auto_awesome

Analytical Summary

Vistagen Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $13.7M
Dividend Yield —
Revenue Growth 161.1% ↗
Op. Margin None
ROIC -203.1% ↘
FCF / Share $-1.74 ↘
Trailing P/E —
Price / Book 0.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

28-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.27M
↑ +161.1% —
Net Income Profit after all expenses
$-69.69M
↓ -35.5% —
Operating Margin Operating profit as % of sales
-344.6%
↓ -8.7% —
FCF / Share Free cash flow per share
$-1.74
↓ -28.0% —
Long-Term Debt Long-term obligations
$58.80K
↓ -97.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
3
Financial Health ↓
2
Cash Quality →
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 28 years · 78 quarters